PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
NCT00380601 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2009-12-23
Summary
An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA
Conditions
Interventions
- DRUG
-
MRA(Tocilizumab)
8mg/kg/4 weeks
Sponsors & Collaborators
-
Chugai Pharmaceutical
lead INDUSTRY
Principal Investigators
-
Yuji Kimura · Chugai Pharmaceutical Co., Ltd. Research Dept.1
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-05-31
- Primary Completion
- 2008-08-31
- Completion
- 2009-02-28
Countries
- Japan
Study Locations
More Related Trials
-
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)
NCT00144521 ·Status: COMPLETED ·Phase: PHASE3
-
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
NCT00144560 ·Status: COMPLETED ·Phase: NA
-
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144612 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
NCT00144573 ·Status: COMPLETED ·Phase: NA
-
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144599 ·Status: COMPLETED ·Phase: PHASE3
-
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144664 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
NCT00144625 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
NCT00661284 ·Status: COMPLETED
-
The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis
NCT04384068 ·Status: UNKNOWN
-
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01347983 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
NCT01332994 ·Status: COMPLETED ·Phase: PHASE3
-
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
NCT00720798 ·Status: COMPLETED ·Phase: PHASE3
-
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation
NCT01120366 ·Status: COMPLETED ·Phase: PHASE4
-
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
NCT00721123 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients
NCT01258712 ·Status: COMPLETED ·Phase: PHASE3
-
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
NCT02404558 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
NCT01988012 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
NCT02046603 ·Status: COMPLETED ·Phase: PHASE3
-
Usefulness of Non TNF Usage in RA Patients
NCT03784261 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
NCT00848120 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Rheumatoid Arthritis
NCT01253265 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.
NCT00773461 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
NCT00074438 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
NCT03605251 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
NCT01254331 ·Status: COMPLETED ·Phase: PHASE3